| Ytd | -97.20% | |
| 1y | -95.06% |
| Open | 18.99 | Prev Close | 18.82 | Low | 18.54 | High | 19.14 | Mkt Cap | 5.23M |
| Vol | 11.12K | Avg Vol | 59.47K | EPS | -106.20 | P/E | -0.18 | Forward P/E | -5.68 |
| Beta | 1.40 | Short Ratio | 2.27 | Inst. Own | 25.53% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-11 | 50-d Avg | 20.08 | 200-d Avg | 229.00 | 1yr Est | 9.00 |
QNCX News
Leerink Partners analyst Joseph Schwartz initiates coverage on Quince Therapeutics (NASDAQ:QNCX)
Cantor Fitzgerald analyst Olivia Brayer Saunders initiates coverage on Quince Therapeutics (NASDA
The acquisition is structured as a stock-for-stock merger, pursuant to which all outstanding equity
Data from Phase 2a study of LAM-001 on top of standard of care in PH-ILD patients with refractory PH
US stocks rose, Dow up 2.85%, Nasdaq up 3.33%, S&P 500 up 2.54%. Consumer discretionary shares u
Levi Strauss (LEVI) reported strong Q1 2026 results, raising revenue & earnings guidance. Other
Quince Therapeutics, Inc. (Nasdaq: QNCX) today announced the successful settlement of the company
Quince Therapeutics shares surged 53% after hours Thursday following the engagement of LifeSci Capit
Quince Therapeutics stock is trading sharply lower Thursday after the biotech company followed up We
During Wednesday's trading, 517 companies set new 52-week lows.
On Thursday, 1076 companies hit new 52-week lows.
On Wednesday, 340 stocks hit new 52-week lows.
On Tuesday, 250 stocks hit new 52-week lows.